Comment

+12 pts

RVNC

Daxxify Positioned to Disrupt. Initiating Coverage at Buy. PT $33.

As a commercial-stage biotechnology company focused on the development of cosmetic injectable and therapeutic neuromodulator products, we see the recent (Sept 8) FDA approval of...

By ethonomics on Sept. 22, 2022, 5:03 p.m.
Tagged topics: initiation report
Views: 7, Votes: 3, Responses: 0, Attachments: 1

Please login to view full post with attachments.

Signup/Login to collect points for voting and responding. Points can be used to unlock content.

Similar posts others by others on these stocks